NZM2.BE - Novozymes A/S
| Chiusura precedente | 46,97 |
| Aperto | 47,09 |
| Denaro | 44,80 x 50000 |
| Lettera | 46,27 x 50000 |
| Min-Max giorno | 45,49 - 47,09 |
| Intervallo di 52 settimane | 44,09 - 63,04 |
| Volume | |
| Media Volume | 7 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireNovozymes delivers stronger than expected Q1 results
After the first quarter of 2023, Novozymes delivers stronger results than expected with 5% organic sales growth. The company confirms the 2023 outlook of 4-7% which is expected to be driven by pricing and volume growth. COPENHAGEN, Denmark – April 26, 2023. In the first three months of the 2023 financial year, Novozymes delivers 5% organic sales growth, an EBIT-margin of 26.0% before special items, and ROIC including goodwill of 17.7% before special items. A solid start to the year and a strong
- GlobeNewswire
Novozymes’ and Chr. Hansen’s shareholders approve combination to create a leading global biosolutions partner
The proposed combination of Novozymes and Chr. Hansen has now been approved by each company’s respective shareholders, and with strong support from the shareholders the two biosolutions companies are now one step closer to uniting. The new company is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large. COPENHAGEN, Denmark – March 30, 2023. Today, Novozymes and Chr. Hansen held their respective extraordinary gener
- GlobeNewswire
Invitation to an extraordinary shareholders’ meeting of Novozymes A/S
To the shareholders of NovozymesThe Board of Directors is pleased to invite you to an extraordinary shareholders’ meeting of Novozymes to be held on Thursday March 30, 2023 at 12:00 (noon) CEST at Ballerup Super Arena. Please read the invitation in PDF Til Novozymes’ aktionærerBestyrelsen har hermed fornøjelsen af at invitere til ekstraordinær generalforsamling i Novozymes torsdag den 30. marts 2023 kl. 12.00 i Ballerup Super Arena. Læs venligst den fulde invitation i PDF format Attachments Noti
- GlobeNewswire
Invitation to Novozymes' annual shareholders' meeting 2023
To the shareholders of Novozymes A/S The Board of Directors is pleased to invite you to the company's annual shareholders' meeting on Thursday March 2, 2023 at 4:00 pm CET at Ballerup Super Arena Please read the invitation in PDF Til Novozymes A/S' aktionærer Betyrelsen har hermed fornøjelsen af at invitere dig til selskabets ordinære generalforsamling torsdag den 2. marts 2023 kl. 16.00 i Ballerup Super Arena Læs venligst den fulde invitation i PDF format Attachments Invitation to Novozymes' An
- GlobeNewswire
Novozymes delivers historically strong full-year results
Novozymes is delivering strong growth and earnings in a volatile market environment with 9% organic sales growth in 2022. This marks the highest organic sales growth in more than a decade, and Novozymes is confident about the 2023 outlook of 4-7%. COPENHAGEN, Denmark – January 26, 2026. In the 2022 financial year, Novozymes delivers 9% organic sales growth – 11% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 26.4%, and ROIC including goodwill before
- GlobeNewswire
Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner
Today, Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. The combination is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large. COPENHAGEN, Denmark – December 12, 2022. The proposed combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") will create a strong biosolutions group wi
- GlobeNewswire
As one of the first companies in the world, Novozymes has had its net-zero target validated by the Science Based Targets initiative
Novozymes has renewed its climate targets and by 2030 will reduce its absolute CO2 emissions across its operation by 75% and reduce its absolute CO2 emissions from its supply chain by 35%. By 2050, Novozymes will reach net-zero. COPENHAGEN, Denmark – November 10, 2022. Novozymes’ first science-based targets were approved in 2019. Today Novozymes has new, SBTi approved near and long-term science-based emission reduction targets and is one of the first companies in the world to have committed to S
- GlobeNewswire
Novozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth
COPENHAGEN, Denmark – November 10, 2022. Novozymes, the world leader in biological solutions, and LinusBio (Linus Biotechnology Inc.), a leader in precision exposome sequencing, today announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial. The project will apply LinusBio’s environmental biodynamics platform, enabling detailed temporal mapping of harmful compound exposure, to a clinical trial of probiotics sponsored by Novozymes’ human healt
- GlobeNewswire
Novozymes confirms upgraded guidance by strong start to Q4
Novozymes delivered 9% organic sales growth in the first nine months of 2022 and 6% organic sales growth in the third quarter. As announced on October 7, the full-year organic sales growth outlook was raised from 6-8 % to now 8-9 % following a strong performance in the first nine months of the year, and expectedly, continued strong Q4 momentum. COPENHAGEN, Denmark – November 3, 2022. In the first nine months of the 2022 financial year, Novozymes delivers 9% organic sales growth, an EBIT-margin o
- GlobeNewswire
Novozymes Named EPA Safer Choice Partner of the Year for Second Consecutive Year
Novozymes Named EPA Safer Choice Partner of the Year for Second Consecutive Year World’s Leading Biotech Powerhouse Recognized for Providing and Advocating for Ingredients that Create Safer Detergents Franklinton, NC – November 1, 2022. Novozymes was named a 2022 Safer Choice® Partner of the Year by the U.S. Environmental Protection Agency (EPA) for outstanding achievement in the manufacture of ingredients that are safer for families, pets, workplaces, communities, and the environment. Novozymes
GlobeNewswireBiotalys and Novozymes announce successful Evoca™ feasibility study
Partners identify new ways to scale Biotalys’ first biofungicide more cost-efficientlyGhent, BELGIUM and Copenhagen, DENMARK , Oct. 24, 2022 (GLOBE NEWSWIRE) -- Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions, and Novozymes, a world leader in biotech solutions including Ag biologicals, today announced the successful outcome of the feasibility study for Evoca™*, Biotalys’ first proprietary biocontrol product
- GlobeNewswire
Novozymes delivers strong half year results and narrows full-year outlook upwards
Novozymes delivered solid earnings and double-digit organic sales growth in both the first half and in the second quarter. Despite the volatile market environment, the company narrows its full-year organic sales outlook upwards from 4-8% to now 6-8% and raises EBIT-margin expectations from 25-26% to now 26-27%. COPENHAGEN, Denmark – August 11, 2022. Novozymes delivers 10% organic sales growth and an EBIT-margin of 26% in the first half of the year, with 18% organic sales growth in DKK. Good mome
- GlobeNewswire
Novozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming cost
Novozymes has experienced unprecedented cost-inflation on raw materials, energy, and logistics. To recover these headwinds, substantial price increases will be implemented. COPENHAGEN, Denmark – 15 July 2022. Novozymes has been able to partially shield its customers from a large part of the global challenges, securing business continuity and high price stability relative to other suppliers. However, Novozymes will further substantially increase prices at a level at least in line with the current